FDA Clearance Tracker · DEN220025
Phagenyx System
Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Sep 16, 2022
De Novo granted
Time to decision
150 days
Received Apr 19, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN220025
- Device name
- Phagenyx System
- Applicant
- Phagenesis Limited
- Applicant location
- Manchester, GB
- Received
- Apr 19, 2022
- Decided
- Sep 16, 2022
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Oropharyngeal Electrical Stimulator (QQG)
- Device class
- Class II
- Regulation
- 21 CFR 874.5950
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN220025
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Phagenesis Limited
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.